Form 4: Puma Biotechnology Director Sells Over 10,000 Shares Under Pre-Arranged Plan

Troy Edward Wilson, a Director at Puma Biotechnology, Inc. (PBYI), sold 10,800 shares of common stock on June 13, 2025, through a pre-arranged 10b5-1 trading plan.

Summary

• Troy Edward Wilson, a Director of Puma Biotechnology, Inc. (PBYI), executed a sale of 10,800 shares of the company's common stock.
• The transaction occurred on June 13, 2025, and was conducted pursuant to a Rule 10b5-1(c) trading plan, which was adopted on March 12, 2025.
• The shares were sold at a weighted average price of $3.40 per share, with individual transaction prices ranging from $3.34 to $3.50.
• Following this transaction, Mr. Wilson directly beneficially owns 43,550 shares of Puma Biotechnology common stock.
• Additionally, Mr. Wilson indirectly beneficially owns 400 shares through Child #1 and 150 shares through Child #2.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While an insider sale can be perceived negatively, the fact that it was conducted under a pre-arranged 10b5-1 plan mitigates immediate concerns about a sudden loss of confidence, suggesting a planned financial move rather than a reactive one.

Negatives

• The sale of shares by a company director, even under a pre-arranged plan, can sometimes be interpreted by investors as a signal of reduced confidence in the company's near-term prospects or a desire for diversification.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a routine disclosure of an insider stock transaction and does not provide broader industry context or trends. Insider sales are common for various personal financial planning reasons, including diversification or liquidity, and are often pre-scheduled via 10b5-1 plans.

Related Party Transactions

• The reported transaction is a sale of common stock by a director, which is a related party transaction under SEC rules.

Stakeholder Impact

• Shareholders: May interpret the director's sale as a signal, potentially influencing their perception of the stock, though the 10b5-1 plan suggests a pre-planned financial decision rather than a reactive one.

Key Dates

Keywords

Puma Biotechnology, PBYI, Insider Trading, Stock Sale, Form 4, Director Sale, 10b5-1 Plan, Equity Transaction